Elf Sanofi

Sanofi

Sanofi Sa

Jacques Simiand

Jean-Claude Vernieres

Etienne Mendes

Peter Keane

Alberto Bianchetti

Andre Bachy

Laurent Fraisse

Gerard R Le Fur

Tiziano Croci

Philippe Soubrie

Michel Morre

Peter E Keane

Peter-Eugene Keane

Jean-Claude Verniere

A compound of formula ##STR1## in which A represents S; R.sub.1 is selected from the group consisting of OH, (C.sub.1 -C.sub.12)alkyl, (C.sub.1 -C.sub.12)alkoxy, benzyloxy, phenyl, benzyl (C.sub.1 -C.sub.4)alkyl NZ.sub.1 Z.sub.2, and NZ.sub.1 Z.sub.2 ; R.sub.2 is selected from the group consisting of OH, SH, (C.sub.1 -C.sub.4)alkoxy, (C.sub.1 -C.sub.4)alkylthio, and NZ.sub.1 Z.sub.2 ; R.sub.3 is selected from the group consisting of H, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkylthio, (C.sub.1 -C.sub.4)alkoxy, phenyl, and benzyl; B is selected from the group consisting of phenyl; pyridyl; phenyl substituted by one or more groups selected from halo, (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, CF.sub.3, CH.sub.2 NZ.sub.1 Z.sub.2, and NZ.sub.1 Z.sub.2 wherein Z.sub.1 and Z.sub.2 are selected, independently of each other, from the group consisting of H, (C.sub.1 -C.sub.6)alkyl, formyl, and benzyl or --NZ.sub.1 Z.sub.2 is selected from the group consisting of pyrrolidinyl, piperidinyl, morpholino, hexahydroazepino, ##STR2## piperazino, piperazino substituted in position 4 by (C.sub.1 -C.sub.8)alkyl, benzyl or diphenylmethyl; and pyridyl substituted by one or more groups selected from halo, (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, CF.sub.3, CH.sub.2 NZ.sub.1 Z.sub.2, and NZ.sub.1 Z.sub.2 wherein Z.sub.1 and Z.sub.2 are selected, independently of each other, from the group consisting of H, (C.sub.1 -C.sub.6)alkyl, formyl, and benzyl, or NZ.sub.1 Z.sub.2 is selected from the group consisting of pyrrolidinyl, piperidinyl, morpholino, hyxahydroazepino, ##STR3## piperazino, and piperazino substituted in position 4 by (C.sub.1 -C.sub.8)alkyl, benzyl or diphenylmethyl; or its salt with an acid or a base.

Heterocycle-coupled substituted pyrrolo[3,2-c]pyridin-2-carboxylic acids

Compounds of formula ##STR1## in which R.sub.1 represents OH, (C.sub.1 -C.sub.12)alkyl, (C.sub.1 -C.sub.12)alkoxy, benzyloxy, benzyl, phenyl, (C.sub.1 -C.sub.4)alkylNZ.sub.1 Z.sub.2 or NZ.sub.1 Z.sub.2 ; R.sub.2 represents OH, SH, (C.sub.1 -C.sub.4)alkoxy, (C.sub.1 -C.sub.4)alkylthio or NZ.sub.1 Z.sub.2 ; R.sub.3 represents H, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkylthio, (C.sub.1 -C.sub.4)alkoxy, phenyl or benzyl; A represents N and R represents H or (C.sub.1 -C.sub.4)alkyl which can be substituted by phenyl or NZ.sub.1 Z.sub.2 ; B represents phenyl which is coupled to the pyridyl ring and is optionally substituted by one or more groups chosen from halo, (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, CF.sub.3, CH.sub.2 NZ.sub.1 Z.sub.2 or NZ.sub.1 Z.sub.2 ; and Z.sub.1 and Z.sub.2 represent, independently of each other, H, (C.sub.1 -C.sub.6) alkyl, formyl or benzyl, or they form with the nitrogen atom to which they are attached an optionally substituted saturated heterocycle and their salts.

Substituted thienyl- or pyrrolylcarboxyclic acid derivatives, their

The invention concerns a method of treatment and prophylaxis of depression and stress by means of a phenylethanolaminotetralin of formula (I) ##STR1## wherein A is a (C.sub.1 -C.sub.4)alkylene radical and R represents a hydrogen atom or a (C.sub.1 -C.sub.4)alkyl group, or a pharmaceutically acceptable salts thereof.

Method of treatment or prophylaxis of depression and stress

A method of treatment of anxiety and depression in mammals is described which comprises administering to a mammal in need thereof an effective amount of a trifluoromethylphenyl-tetrahydropyridine derivative of formula I ##STR1## wherein Alk represents a straight or branched (C.sub.1 -C.sub.4)alkylene chain and R is selected from the group consisting of cyano, acetyl, (C.sub.3 -C.sub.7)cycloalkyl, pyridyl, 1-oxide-pyridyl and naphthyl, or of a pharmaceutically acceptable salt thereof.

Method of treatment of anxiety and anxio-depressive disorders

The present invention concerns new derivatives of 4-oxo-1,4-dihydro-quinoline 3-carboxamide, answering to the following general formula: ##STR1## in which: R.sub.1 represents a linear or branched lower alkyl radical, containing from 1 to 5 carbon atoms; an alkenyl or alkynyl radical containing from 2 to 5 carbon atoms; or a cycloalkyl radical containing from 3 to 5 carbon atoms,

N-alkoxyalkyl derivatives of quinolone carboxamides

The present invention relates to new quinolylglycinamide derivatives corresponding to the following general formula: ##STR1## The invention also relates to a process for preparing these compounds and their therapeutic application as a psychotropic agent.

Growing community of inventors

Muret, France

Jacques Simiand